Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 1
2025 3
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P, Dumbrava EE. Santin AD, et al. J Clin Oncol. 2024 Oct 10;42(29):3421-3429. doi: 10.1200/JCO.23.02767. Epub 2024 Jul 31. J Clin Oncol. 2024. PMID: 39083724 Free PMC article. Clinical Trial.
PURPOSE: Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immunotherapy have poor prognosis. We report efficacy and safety of sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-di …
PURPOSE: Patients with advanced endometrial cancer (EC) who progress on or after platinum-based therapy and immu …
Update Gynecologic Malignancies 2025 - Expert Opinion on Systemic Therapy for Early and Advanced Gynecological Cancers.
Emons J, Gocke J, Schulmeyer C, Stübs FA, Krückel A, Amann N, Beckmann MW, Hörner M, Pöschke P. Emons J, et al. Geburtshilfe Frauenheilkd. 2025 Jun 30;85(7):736-745. doi: 10.1055/a-2622-0684. eCollection 2025 Jul. Geburtshilfe Frauenheilkd. 2025. PMID: 40599899 Free PMC article.
This review aims to summarize the latest studies and developments in the therapeutic landscape of endometrial, ovarian, and cervical cancer. The treatment of advanced endometrial cancer has changed significantly with the introduction of CPI such as dostarlima …
This review aims to summarize the latest studies and developments in the therapeutic landscape of endometrial, ovarian, and cervical cancer. …
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
Bujnak AC, Solaru SA, Tewari K. Bujnak AC, et al. Gynecol Oncol. 2025 Apr;195:180-191. doi: 10.1016/j.ygyno.2025.03.013. Epub 2025 Mar 25. Gynecol Oncol. 2025. PMID: 40139025 Free article. Review.
With significant overall survival benefits reported in several phase 3 randomized clinical trials, the integration of anti-PD-1 immunotherapy with systemic chemotherapy has transformed the therapeutic landscape in advanced endometrial cancer …
With significant overall survival benefits reported in several phase 3 randomized clinical trials, the integration of anti-PD- …
Gynecologic cancers in 2025: a year in review.
Arenhardt MP, Tavares Filgueiras AB, Alves CB, Nogueira-Rodrigues A. Arenhardt MP, et al. Int J Gynecol Cancer. 2026 Feb;36(2):104463. doi: 10.1016/j.ijgc.2025.104463. Epub 2026 Jan 3. Int J Gynecol Cancer. 2026. PMID: 41564592 Review.
In endometrial cancer, the Cancer Genome Atlas-based molecular classification increasingly informs risk stratification and adjuvant tailoring; long-term PORTEC-3 data refine escalation for p53-abnormal disease and de-escalation considerations for POLE-mutant tumors. …
In endometrial cancer, the Cancer Genome Atlas-based molecular classification increasingly informs risk stratification and adj …
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.
McNamara B, Mutlu L, Greenman M, Harold J, Santin A. McNamara B, et al. Cancers (Basel). 2023 Aug 14;15(16):4085. doi: 10.3390/cancers15164085. Cancers (Basel). 2023. PMID: 37627113 Free PMC article. Review.
Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are two rare histologic variants of uterine carcinoma, with distinct molecular profiles and aggressive metastatic potential. As the effectivity of traditional platinum-based chemotherapy for USC and UCS is low …
Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) are two rare histologic variants of uterine carcinoma, with distinct molecul …
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N. Eskander RN, et al. Int J Gynecol Cancer. 2026 Jun;36(6):102654. doi: 10.1016/j.ijgc.2025.102654. Epub 2025 Sep 7. Int J Gynecol Cancer. 2026. PMID: 41073155 Free article. Clinical Trial.
Sacituzumab govitecan is a trophoblast cell-surface antigen 2-directed antibody-drug conjugate approved for certain types of breast cancer. In the phase II TROPiCS-03 trial, sacituzumab govitecan demonstrated encouraging efficacy and manageable safety in heav …
Sacituzumab govitecan is a trophoblast cell-surface antigen 2-directed antibody-drug conjugate approved for certain typ …
HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract.
Alzayadneh E, Dibbern ME, Rabban J, Fadare O, Mills AM. Alzayadneh E, et al. Int J Gynecol Pathol. 2026 May 7. doi: 10.1097/PGP.0000000000001187. Online ahead of print. Int J Gynecol Pathol. 2026. PMID: 42095344
The DESTINY-PanTumor02 study demonstrated strong responses to Trastuzumab Deruxtecan (T-Dxd), an antibody-drug conjugate targeting HER2, in multiple HER2+ chemoresistant tumors, including gynecologic carcinomas. ...We assessed HER2 and FOLR1 immunohistochemic …
The DESTINY-PanTumor02 study demonstrated strong responses to Trastuzumab Deruxtecan (T-Dxd), an antibody-drug conjugate …
Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence.
Ismaili N. Ismaili N. Biomedicines. 2026 Jan 28;14(2):295. doi: 10.3390/biomedicines14020295. Biomedicines. 2026. PMID: 41751194 Free PMC article. Review.
Results: From 1842 records, 23 studies met inclusion criteria (17 phase-III RCTs and 6 non-phase III RCTs/early-phase studies), distributed as follows: cervical cancer (9 studies, 39%), ovarian cancer (9 studies, 39%), endometrial cancer (4 studies, 17.5%), and vulv …
Results: From 1842 records, 23 studies met inclusion criteria (17 phase-III RCTs and 6 non-phase III RCTs/early-phase studies), distributed …
Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology.
Cassaniti M, Morelli I, Boschi AC, Scodes S, Comerci G, Casanova C, Tamberi S. Cassaniti M, et al. Cancers (Basel). 2026 Jun 4;18(11):1837. doi: 10.3390/cancers18111837. Cancers (Basel). 2026. PMID: 42279419 Free PMC article. Review.
The therapeutic landscape of advanced and recurrent endometrial cancer (EC) has evolved substantially in recent years due to the integration of molecular classification and novel systemic therapies. ...In the post-platinum setting, combinations such as …
The therapeutic landscape of advanced and recurrent endometrial cancer (EC) has evolved substantially in recent years d …